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Let me start by defining ``tropical diseases for the purpose of this presentation. At the
National Institute of Allergy and Infectious Diseases (NIAID), we define "tropical diseases '
as those infectious conditions which affect the citizens of tropical or developing countries
more severely than their countarparts in economically advanced countries. The NIAID ap-
proach, therefore, is broader than the six diseases (e. g. filariasis, leishmamasis, leprosy,
malaria, schistosomiasis, and trypanosomiasis of the UNDP/World Bank/WHO Special Pro､
gram for Research and Training in Tropical Diseases (TDR/WHO)､ It also is more restricted
than the health priorities of development agencies (e･ g. USAID, ｢WHO) which have defined
international health priorities in terms of conditions which produce preventable death and
disease in vulnerable populations (e･ g. acute respiratory infections, diarrhea! diseases, viral
infections, and parasitic diseases).
This audience will also appreciate that the U. S. A. with its diverse populations and
economic disparities is still in many respects a developing country with health indices worse
than some developing countries. Furthermore, large areas of the U. S･ A. are semi-tropical
while Southern Florida, Puerto Rico, the Virgin Islands, and the Pacific Trust Territories are
truly tropical. Tropical diseases, therefore, which 19th Century Europe considered dangers to
expatnots and expeditionary forces were endemic diseases in much of the U･ S. A. Foggy
Bottom where our State Department now stands was once notorious for its malarial fevers.
Thousands of workers died of malaria, cholera, and yellow fever constructing the Chesapeake
and Ohio Canal which starts near Foggy Bottom and runs through Georgetown to the interior
in West Virginia. In Abraham Lincoln's day, you could tell a Mississippi Valley settler from
the ravages of relapsing malaria and our Southern populations were notorious for their torpor
brought on from poor nutrition, malaria, and hookworm infections. Indeed, at the same time
that the Nagasaki Institute of Tropical Medicine was established, the U･ S. Government
found it necessary to set up what is now our Centers for Disease Control in Atlanta to con-
trol malaria in civilian and military populations･
To this day, tropical diseases persist in the U. S. A. to a degree not seen in Europe or
Japan. Even where they have disappeared, the potential for reintroduction continues through
persistence of efficient vectors and/or poor sanitary practices. The U. S･ A､, for example, has
persistent foci of malaria in the San Diego area, cholera in the Gulf of Mexico, leishmaniasis
in south Texas, and schistosomiasis in Puerto Rico. Sylvatic plague is well established west
of the Mississippi and zoonotic rabies (foxes, skunks, bats, raccoons) exists in most areas.
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Several years after my graduation from the London School of Hygiene and Tropical
Medicine (LSHTM) the late Professor Bruce-Chwatt was disappointed to learn that CDC had
assigned me to be State Epidemiologist for Virginia･ He was pleased when I told them that
LSHTM had been excellent training for my new assignment･
Because many tropical diseases still persist or pose a threat to U･ S. citizens, several
U･ S･ Government agencies snare responsibilities in tropical medicine. The major players are
the National Institutes of Health (NIH), the Centers for Disease Control (CDC), the U. S. Army,
the U. S. Navy, and the U･ S. Agency for International Development (USAID), NIH is a
civilian agency heavily committed to basic research, prevention research (e. g･ vaccine
development), and clinical research･ CDC, as its name indicates, is responsible for
surveillance and prevention of control programs. The Army and the Navy are both concerned
with the prevention or treatment of tropical diseases in active duty military arid dependents.
USAID is responsible for international technical assistance and economic development･
My further remarks will concentrate on NIH research in general and NIAID tropical
medicine research in particular. While NIH can trace its history to the founding of the
Bacteriology Laboratory at the Marine Hospital on Staten Island, New York in 1888, the
modern NIH began only in 1935 when President Franklin Roosevelt decided to put the scat-
tered Government laboratories doing health research on one site to reach what we now call a
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"critical mass. The new NIH was placed on "Tree Tops , a 19 hectare estate in rural
Bethesda, Maryland. "Tree Tops 'had recently been donated to the Government by Mr.
Luke Wilson, a New Dealer and Roosevelt admirer･ The second most significant event in
creating NIH was the U. S. Government's decision following World War H to transfer the
grants program of the War Department s Office of Scientific Research and Development ex-
tramural programs to the NIH. Before this decision, NIH was not a significant funding
source for U. S. universities･ Tropical medicine and infectious diseases comprised a signifi-
cant portion of this war-related research portfolio. NIH, therefore, inherited an ongoing
research effort which among its many accomplishments had developed chloroquine and
penicillin.
From 1946- 1967, the NIH Office of International Research managed most externally
funded tropical disease research･ In 1968, however, the Fogarty International Center was
established to coordinate NIH international activities･ The NIH Office of International
Research disbanded and international research awards were transferred to the appropriate
line institute at NIH. Tropical medicine research awards, including the International Centers
for Medical Research and Training (ICMRT) came to NIAID. NIAID continlユes to support
over 95% of NIH's tropical disease effort､
In FY 1991, NIAID Tropical Medicine Research (Handout 1) consisted of 435 research
grants, four research contracts and 41 intramural research projects with a total budget of
8 million or 9.8% of NIAID research. The fact that over 90%" is carried out through com-
petitive extramural research awards is consistent with the 9:1 overall extramlユral/intramural
ratio at NIH. An important point to make is that most of this research is done by U. S. in-
vestigators in the U. S. A. NIAID support for tropical medicine has grown at the same pace
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as non･tropical infectious diseases･ This is a reflection of research opportunities m these
diseases and the high quality of the investigator-initiated research proposals submitted to
NIH, not priority treatment for tropical medicine･
NIAID is a domestic research agency which does not have an international budget. Our
mandate to conduct international research is based on the Public Health Service (PHS) Act
of 1963 which authorized NIH to conduct international research relevant to the health and
safety of U. S. populations wherever they might be. This authorization did not permit NIH
or CDC to provide technical assistance, transfer technology or strengthen institutions outside
the U. S. A. In the U. S. Government, these activities have been the responsibility of the
USAID. The PHS Act of 1988 (often referred to as the ``AIDS" Act), however, modified our
mandate to conduct international research for the first time in 25 years･ It authorized NIH
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and CDC to carry out ``usAID-type 'activities internationally in AIDS-especially in Africa
and the Caribbean. As is frequently the case, however, we were given this authority but no
additional funds to carry it out.
Despite its domestic mandate, NIAID has a low･profile, but extensive international
health research effort､ The mechanisms we use with illustrative examples are summarized in
Handout 2. Briefly, the mechanisms are; 1) intramural collaborative research and research
training; 2) foreign research awards; 3) domestic research awards with a foreign component;
4) official bilateral programs; and 5) international agencies and organizations･
Let me illustrate these mechanisms with respect to Japan. Intramurally, 34 (13.5%) of
the foreign scientists at NIAID last year were from Japan. While we have made awards
directly to Japanese investigators in the past, we currently have no active foreign awards in
Japan. The major portion of NIAID international activities are supported through grant ap-
plication from U. S. scientists to fund research that has an international component･ We have
found, however, that research applications involving collaboration with scientists in develop､
mg countries on tropical diseases do not compete successfully in the NIH peer review pro-
cess. NIAID, therefore, has created three special extramural and one intramural programs to
fulfill our research mission in tropical diseases･ They are:
O NIAID Intramural Tropical Disease Research Center (INCIDR), INCIDR consists
primarily of the Laboratory of Parasitic Diseases (LPD/NIAID) and the recently
established Laboratory of Malaria Research (LMR/MAID).
O Tropical Disease Research Units (TDRU)､ TDRUs support domestic U. S､
multidisciplmary centers of excellence in tropical medicine. About 25% of TDRU
research involves international collaboration.
O International Collaboration for Infectious Disease Research (ICIDR) Awards. An
ICIDR is a linkage award to a U. S. institution to conduct collaborative research
､
with counterparts in a developing country. Approximately 70% of the research is
m the host country･
o Tropical Medicine Research Centers (TMRC)･ T血RCs are research centers of ex-
cellence which receive NIAID directly･ All the research is done in the tropics.
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Special mention should be made of the U. S.-Japan Cooperative Medical Sciences Pro-
gram (CMSP). Established in 1965, this Program is unique among U. S. bilateral programs in
two respects: 1) it is managed by working scientists rather than administrators; and 2) it is
concerned with the health problems of Asia rather than just Japan or the U･ S. A. NIAID
provides the U･ S･ Secretariat for overall U. S.-Japan CMSP and seven of the nine U. S.
Panels and one Board in the CMSP. The U･ S､-Japan Panels on Parasitic Diseases, Viral
Diseases, AIDS, Cholera, Hepatitis, Leprosy, and Tuberculosis are particular･ly relevant to
the tropical medicine research activities of both countries. NIAID values the U･ S.､Japan
CMSP for the opportunity it provides not only to interact with the Japanese scientific com-
munity, but to access industry and policy makers through scientific rather than foreign policy
or political channels.
During W､orld War H, U. S. tropical medicine research policy was d五rected by the
military with scientific guidance and advise from the Armed Forces Epidemiology Board
(AFEB)-on which the U. S.-Japan CMSP is modeled. After the War, interest in interna-
tional research became more prominent as the U. S･ Government committed itself to
assisting with the reconstruction of institutions, training of scientists, and support for
research in war-ravaged Europe countries and Japan. A similar effort to bu､ild biomedical
research capability in newly independent countries of Africa and Asia, however, did not
emerge as a major feature of U･ S. research policy. The rationale for this was complex and
beyond the scope of this presentation. Tropical medicine research needs, r･esources, and
policy were, however, re-examined periodically from 1946- 1962 through Conferences spon-
sored by the U. S･ Army, NIH, and the Rockefeller Foundation and attended by eminent
scientists-not just in tropical medicine, but in biomedical sciences. One of the many
casualties of the Vietnam War was the break､up of this military-scientific､private sector
alliance.
By 1982, interest in and support in the U. S. A. for tropical disease research had flagg-
ed. Ironically, this decline was occurring at a time when scientific advances in immunology
and molecular biology were revolutionizing microbiological research and providing the scien-
tific basis for the development of immunodiagnostic tests, drugs, and vaccines｡ Furthermore,
the division of tropical disease among the several agencies raised obvious doubts in the Ex-
ecutive Branch and Congress regarding duplication of effort and waste ofヒax dollars on
diseases which were not major problems in the U. S. A. External events sue】i as a Deparト
ment of Defense (DoD) decision to shut-down the overseas laboratories of the U･ S. Army
(Brazil, Kenya, Thailand) and Navy (Egypt, Indonesia, Peru, and Philippines), a Congres-
sional study of the activities of the Gorgas Memorial Laboratory (Panama), and an effort by
the new Thatcher administration to close the LSHTM prompted the American Society of
Tropical Medicine and Hygiene (ASTMH) to approach Congress and the National Academy
of Science (NAS) to study the state of Tropical Medicine in the U. S. A.
This concern led to a Congressional directive that its Office of Technology Assessment
(OTA) examine the status of biomedical research and technologies for controlling tropical in､
fectious diseases･ The OTA report Status of Biomedical Research and Related Technology
for Tropical Diseases appeared in 1985. Building on the OTA findings, the U. S･ Army
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Research and Development Command (USARDC), NIAID, CDC, USAID, and the Rockefeller
Foundation funded the Board on Science for Technology and International Development, Na･
tional Research Council (BOSTID/NRC) and the Institute of Medicine, National Academy of
Sciences (IOM/NAS) to conduct an external evaluation entitled The U､ S. Capacity to Ad-
dress Tropical Disease Problems (1987). Among the major findings of this BOSTID/NRC-
IOM/NAS Report were:
o A need for stronger collaborative research and training relationships with scien､
tists and public health officials in less-developed countries;
o A need for U. S･ investigators to become familiar with tropical diseases and
health conditions in developing countries through residence overseas at a for-
mative stage of their careers;
o An unstable career structure in tropical medicine-particularly for U. S. tropical
health professionals who are broadly trained in science, medicine, public health;
and disease control and field experience in the tropics;
o A need for more U. S･ contributions to the training and development of foreign
competence, particularly in research and disease monitoring.
The Report made both general and specific recommendations to the sponsoring agen-
cies on how to address these problems. Subsequent relevant IOM/NAS external reports have
dealt with Malaria: Obstacles and Opportunities (1991) and Emerging lnfections: Microbial
Threats to Health in the United States (1992).
NIAID has dealt with the recommendations of these reports in the context of the NIH
Strategic Plan being developed under the leadership of Dr･ Bernadine Healy and our own pro-
gram planning process which includes recommendations from the National Advisory Allergic
and Infectious Disease Council (NAAIDC) and two policy retreats each year by the NIAID
leadership and senior staff. NIAID priorities and future directions in tropical infectious
diseases are outlined in the Report of the Task Force on Microbiology and Infectious
Diseases (January, 1992)･ Major Task Force Recommendations included:
O NIAID basic research in infectious diseases should focus on the following four
areas: 1) genetics, molecular biology, and structural biology; 2) pathogenesis; 3)
epidemiology; and 4) immunology;
O Efforts should be made to stimulate more multi-disciplinary research and training
in infectious diseases -including cell biology, immunology, molecular genetics, vac-
cine development, epidemiology, biostatistics, and behavioral research･
O Every effort should be made to facilitate information and technology exchange
among scientists within Government, industry, and academia. This exchange is
critical for the continued development of antimicrobial drugs and vaccines･
o NIAID should continue its longstanding efforts to foster support, and expand
(where possible) broad-based international studies of infectious diseases, including
clinical research, epidemiology, and field trials of promising vaccines and an-
timicrobial drugs･
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In an effort to implement these policy recommendations in tropical i¶しedicine during
the present economic climate, NIAID has established a new program we call the Interna-
tional Centers for Tropical Disease Research (ICTDR) Program. ICTDR brings together the
existing TDRC, TDRUs, ICIDRs, TMRCs, the Office of Tropical Medicine Research in the
NIAID Director's Office (OTMIR/NIAID), the NIAID Division of AIDS (DAIDS/NIAID), and
NIAID､supported Cooperation Groups. DAIDS/NIAID currently supports the International
Cooperation in AIDS Research (ICAR) Program-which is a linkage program similar to the
ICIDR and the new Preparing for AIDS/HIV Vaccine Evaluations (PAVE) Program which
will support U. S. groups to assist institutions in Africa (Kenya, Malawi, Rwanda, Uganda,
and Zimbabwe), Asia (India and Thailand), and the Caribbean (Haiti) get ready to evaluate
promising AIDS vaccine cadidates･ Cooperating Groups are U. S. universities or research in･
stitutions which may not have a TDRU or ICIDR award, but receive substantial NIAID
research support in parasitic diseases or vector biology･
The ICTDR will serve as a network to promote multidisciplmary research and facilitate
information exchange and cooperation among NIAID scientists and NIAID-funded tropical
medicine investigators･ At present, the major ICTDR activity will be a networking meeting
each Spring at NIH. The inaugural ICTDR meeting (W､ashington, DC: 30 April-1 May, 1992
) was preceded by a NIAID-TDR/WHO Forum on "Tropical Diseases (Bethesda, MD: 29
April, 1992). The meetings produced a policy document Current Approaches to Ancient Pro､
blems･ Report of the First Annual Meeting of the NIAID International Centers for Tropical
Disease Research. NIAID has also conducted an inventory of the activities and resources
available at ICTDR participating institutions. This information is contained in the NIAID
document International Centers for Tropical Disease Research: Training and Research
Resources.
In this presentation, I have provided a snapshot of current NIAID tropical infectious
disease priorities and trends･ The Second ICTDR Network Meeting will be held in Bethesda
from April 28-30, 1993. It will be an open scientific meeting in which all interested scien-
tists and institutions are invited to participate. I would like to take this oportunity to extend
an invitation from Dr. Anthony S･ Fauci, NIAID Director to all of you and to the Nagasaki
Institute of Tropical Medicine in particular to come to Bethesda next April to join with
NIAID in tropical disease priority setting and program planning at the national and global
levels.
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